Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer
Wirksamkeit im Versorgungsalltag und prognostische Faktoren von Durvalumab plus Chemotherapie bei fortgeschrittenem biliärem Traktkarzinom
The Oncologist · 04.08.2025 · 30 (8)
DOI: 10.1093/oncolo/oyae306 ↗Auf einen Blick
In einer multizentrischen retrospektiven Kohorte von 45 Patient:innen mit fortgeschrittenem BTC zeigte Durvalumab plus Cisplatin/Gemcitabin eine objektive Ansprechrate von 31,1 % und ein medianes Gesamtüberleben von 15,8 Monaten.
Fragestellung
Wie wirksam ist Durvalumab plus Platin-haltige Chemotherapie in der Erstlinie bei fortgeschrittenem biliärem Traktkarzinom im Versorgungsalltag?
Methode
Retrospektive multizentrische Studie bei Patient:innen mit fortgeschrittenem BTC; Erstlinientherapie mit Durvalumab plus Platin-Chemotherapie zwischen August 2021 und Juni 2023.
Ergebnisse
45 Patient:innen. Objektive Ansprechrate 31,1 % (14 partielle Remissionen), stabile Erkrankung bei 40 % (18). Medianes PFS 5,6 Monate (95 %-KI 4,4–6,9), medianes OS 15,8 Monate (95 %-KI 7,9–23,8).
Einschränkungen
Die höhere Durvalumab-Dosis zeigte nur einen nicht signifikanten Trend zu besserer Wirksamkeit.
Schlussfolgerung der Autor:innen
Die Autor:innen berichten eine mit TOPAZ-1 vergleichbare Wirksamkeit von Durvalumab plus Chemotherapie und benennen ECOG-Status sowie Neutrophilen-Lymphozyten-Ratio als prognostische Faktoren.
Kernaussagen
- ORR 31,1 %; stabile Erkrankung bei 40 %
- Medianes PFS 5,6 Monate, OS 15,8 Monate
- Schlechter ECOG-Status und hohe NLR waren ungünstig
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 20.11.2024. Verfasst von Wen-Kuan Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, …. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Biliary tract cancer (BTC) is an aggressive biliary tract cancer, arising from the bile ducts and gallbladder, with a poor prognosis. The TOPAZ-1 trial of durvalumab plus first-line chemotherapy (gemcitabine plus cisplatin) showed improved survival vs chemotherapy alone. This real-world study aimed to confirm the effectiveness of this regimen.
Methods
This retrospective, multicenter study included patients with advanced BTC treated with first-line durvalumab plus platinum chemotherapy at the Linkou, Taoyuan, and Tucheng branches of Chang Gung Memorial Hospital as well as at Taipei Veterans General Hospital between August 2021 and June 2023.
Results
Among the 45 patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment, the objective response rate was 31.1% (14 partial responses). An additional 40% (18 patients) had stable disease. The median progression-free survival was 5.6 months (95%CI, 4.4-6.9) and median overall survival was 15.8 months (95%CI, 7.9-23.8). Responders had significantly longer survival than non-responders (15.8 vs 3.3 months). Although higher durvalumab doses (1000-1500 mg) appeared to have improved efficacy compared to lower doses (<1000 mg), the difference was not statistically significant. On multivariate analysis, poor ECOG performance status (≥2) and a high neutrophil-lymphocyte ratio were independent prognostic factors for shorter overall survival.
Conclusion
This real-world study demonstrated the comparable efficacy of durvalumab plus chemotherapy to the TOPAZ-1 trial for patients with advanced BTC and identified prognostic factors. There was a trend toward improved efficacy with higher durvalumab dosing (1000-1500 mg) vs lower dosing, though further research is needed to confirm this relationship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
- Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of General Surgery, GIST Team, and Liver Research Center, Chang Gung Memorial Hospital, Linkou Branch, Chang Gung University, Taoyuan, Taiwan.
- Division of Hematology-Oncology, Department of Internal Medicine, New Taipei City Municipal Tucheng Hospital, New Taipei City, Taiwan.
ORCID-Profile: Wen-Kuan Huang
Zitieren
APA
Huang, W. K., Tang, Y. J., Wu, C. E., Hou, M. M., Hsu, H. C., Su, P. J., Chiang, N. J., Chen, S. C., Yeh, C. N., Chen, J. S., Chen, M. H., Hsieh, C. H., & Chou, W. C. (2025). Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer. The Oncologist, 30(8). https://doi.org/10.1093/oncolo/oyae306
Vancouver
Huang WK, Tang YJ, Wu CE, Hou MM, Hsu HC, Su PJ, et al. Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer. The Oncologist. 2025;30(8). doi:10.1093/oncolo/oyae306
BibTeX
@article{Huang2025,
author = {Huang, Wen-Kuan and Tang, Yan-Jei and Wu, Chiao-En and Hou, Ming-Mo and Hsu, Hung-Chih and Su, Po-Jung and Chiang, Nai-Jung and Chen, San-Chi and Yeh, Chun-Nan and Chen, Jen-Shi and Chen, Ming-Huang and Hsieh, Chia-Hsun and Chou, Wen-Chi},
title = {Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {8},
doi = {10.1093/oncolo/oyae306}
}
EUVIMED